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Abstract
Background: Previous studies provide conflicting evidence on whether metformin is pro-
tective against cancer. When studying time-varying exposure to metformin, covariates
such as body mass index (BMI) and glycated haemoglobin (HbA1c) may act as both
confounders and causal pathway variables, and so cannot be handled adequately by
standard regression methods. Marginal structural models (MSMs) with inverse probabil-
ity of treatment weights (IPTW) can correctly adjust for such confounders. Using this
approach, the main objective of this study was to estimate the effect of metformin on
cancer risk compared with risk in patients with T2DM taking no medication.
Methods: Patients with incident type 2 diabetes (T2DM) were identified in the Clinical
Practice Research Datalink (CPRD), a database of electronic health records derived from pri-
mary care in the UK. Patients entered the study at diabetes diagnosis or the first point after
this when they had valid HbA1c and BMI measurements, and follow-up was split into 1-
month intervals. Logistic regression was used to calculate IPTW; then the effect of metfor-
min on all cancers (including and excluding non-melanoma skin cancer) and breast, pros-
tate, lung, colorectal and pancreatic cancers was estimated in the weighted population.
Results: A total of 55 629 T2DM patients were alive and cancer-free at their study entry;
2530 people had incident cancer during a median follow-up time of 2.9 years [interquar-
tile range (IQR) 1.3–5.4 years]. Using the MSM approach, the hazard ratio (HR) for all
cancers, comparing treatment with metformin with no glucose-lowering treatment, was
1.02 (0.88–1.18). Results were robust to a range of sensitivity analyses and remained
consistent when estimating the treatment effect by length of exposure. We also found no
evidence of a protective effect of metformin on individual cancer outcomes.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
International Journal of Epidemiology, 2019, 1–11
doi: 10.1093/ije/dyz005
Original article
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article-abstract/doi/10.1093/ije/dyz005/5307962 by London School of H
ygiene & Tropical M
edicine user on 22 February 2019
Conclusions: We find no evidence that metformin has a causal association with cancer
risk.
Key words: Marginal structural models, inverse probability weighting, type 2 diabetes, metformin, cancer, pharma-
coepidemiology, time-dependent confounding
Introduction
Metformin is the preferred first-line treatment for type 2 di-
abetes (T2DM) in general practices in the UK.1,2 Previous
epidemiological studies have suggested that metformin may
reduce cancer incidence in patients with type 2 diabetes3,4;
others have found no such association.5–7 The potential for
bias in many studies has been highlighted previously.8,9
The highest-quality existing observational studies have
compared new users of metformin with new users of sul-
phonylureas, ignoring subsequent changes in treatment (in-
tention to treat approach),9 and finding no evidence of an
association between metformin and cancer. However, the
use of an active comparator makes it more difficult to at-
tribute any observed effect (or lack thereof) to metformin
itself. Further, patients inevitably switch treatment through
time, so this approach may dilute any real association.
One possible randomized controlled trial (RCT) designed
to examine the causal association between metformin use
and cancer incidence might randomize patients with newly
diagnosed type 2 diabetes to receive either metformin mono-
therapy or placebo, with all participants additionally ad-
vised to follow a standard diet and exercise regimen, and
long follow-up to detect cancer outcomes. Provided there
were no/minimal protocol deviations, notably that patients
stayed on their allocated treatment through follow-up, such
a trial would reliably estimate the effect of metformin on
cancer risk. In reality, although practical constraints pre-
clude such a trial, we may be able to recreate a similar com-
parison in routinely collected primary care records by
comparing initiators and non-initiators of metformin
through time. In the absence of randomization, there is
likely to be time-dependent confounding by factors
associated with both treatment initiation and cancer risk. In
the presence of time-dependent confounders that are them-
selves likely to be affected by previous treatment, such as
body mass index (BMI) and glycated haemoglobin
(HbA1c),10,11 standard statistical methods are unable to es-
timate an unbiased treatment effect.12 Marginal structural
models (MSMs) with inverse probability of treatment
weighting (IPTW) are an established causal inference
method to address such time-dependent confounding.13 The
method creates a weighted population in which treatment
initiation through time is independent of the time-dependent
confounders, and has been widely used in the HIV literature
to assess treatment regimens while controlling for time-
varying CD4.14,15
To date, no studies have used MSMs with IPTW to
compare cancer risk between new users of metformin, and
patients with a diabetes diagnosis who are yet to initiate
any treatment (no medication). Nor have they investigated
the potential for time-dependent confounders when model-
ling time-varying treatment in the context of metformin
and cancer. The main objective of this study was to esti-
mate the causal effect of metformin monotherapy vs no
medication on risk of cancer in patients with newly diag-
nosed T2DM, using MSMs with IPTW to appropriately
deal with time-dependent confounding. We further aimed
to evaluate the impact of adjusting for time-dependent con-
founders by comparing MSMs with standard methods.
Methods
This study is based in part on data from the Clinical Practice
Research Datalink obtained under licence from the UK
Key Messages
• Evidence for a protective effect of metformin on cancer risk remains under debate.
• Existing studies of metformin and cancer may not appropriately deal with time-dependent confounders affected by
previous treatment.
• Inverse probability weighting of marginal structural models can deal with such confounders.
• Using this approach in a cohort of 55 000 patients with newly diagnosed diabetes from the Clinical Practice Research
Datalink [median follow-up 2.9 years (IQR 1.3–5.4 years)] produced no evidence of an association between metformin
use and cancer incidence.
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Medicines and Healthcare products Regulatory Agency. The
data are provided by patients and collected by the NHS as
part of their care and support. The interpretation and con-
clusions contained in this study are those of the author/s
alone. The study was approved by the Independent Scientific
Advisory Committee (approval number: 12_027RA). The
approved protocol was made available to the journal and
reviewers during peer review. Generic ethical approval for
observational research using the Clinical Practice Research
Datalink (CPRD) with approval from ISAC has been granted
by a Health Research Authority (HRA) Research Ethics
Committee (East Midlands – Derby, REC reference number
05/MRE04/87). In addition, the study was approved by the
London School of Hygiene and Tropical Medicine ethics
committee (approval number 6349).
Basic study population
Patients with incident T2DM were identified from the
CPRD [https://www.cprd.com], using an algorithm devel-
oped previously16 (see Supplementary Methods, available as
Supplementary data at IJE online). The algorithm required
a diagnosis code for T2DM alongside either a diabetes-care
related code or a prescription for an oral glucose-lowering
medication [identified using British National Formulary
(BNF) codes17]. Individuals became eligible when both
codes required to fulfil the inclusion criteria were present,
and this was taken as the date of diabetes diagnosis. If there
were >30 days between the first and last code that con-
firmed the diagnoses, or <12 months observation preceding
the first relevant code, the patient was excluded on the
grounds that they might not be an incident case.
Patients with previous cancer, aged <30 or >90 at diag-
nosis, or with missing smoking/alcohol information at dia-
betes diagnosis, were excluded. A minority of patients
lacked a valid BMI or HbA1c (measured within the previ-
ous 3 months) at diagnosis; for these individuals, study en-
try (baseline) was delayed until the point in follow-up
when complete data were available.18 However, patients
who had already commenced glucose-lowering therapy by
this point were excluded (see Supplementary Methods,
available as Supplementary data at IJE online).
Follow-up ended at the earliest of the following: death,
leaving the practice, first cancer record, initiation of any
glucose-lowering medication other than metformin, or the
last data collection date from the practice (31 July 2014 at
the latest).
Exposure definition
The exposure of interest was metformin monotherapy, and
the comparator group was patients with T2DM not taking
any pharmacological therapy (hereafter referred to as ‘no
medication’ controls). The date of metformin initiation
was defined as the date of the first prescription record for
metformin in CPRD (BNF code 6.1.2.2.2). The exposure
status of individuals starting in the no medication group,
who initiated metformin during follow-up, was time-
updated in the month of the first metformin prescription.
Patients were assumed to stay on metformin after their first
prescription, since cessation of metformin without intro-
duction of another glucose-lowering medication would be
unusual and contrary to national guidance.2 All patients
were censored at the initiation of any other glucose-
lowering medication, in order to estimate an ‘as treated’ ef-
fect of metformin monotherapy.
Outcomes
Cancer outcomes were identified using Read codes recorded
in the patient’s CPRD record as described previously.10 The
primary outcomes were all cancers combined, first including
and then excluding non-melanoma skin cancer (NMSC).
Breast, prostate, colorectal and lung cancer outcomes were
investigated individually, as these were the four most com-
mon cancers; and pancreatic cancer was investigated as an
outcome due to its known association with T2DM.19 The
date of cancer diagnosis was brought forward by 6 months
in the primary analysis to minimize reverse causality driven
by undiagnosed cancer affecting diabetes control and thus
treatment.
Statistical analysis
Inverse probability of treatment weighting (IPTW) of
marginal structural models (MSMs) has been described
elsewhere.13,20 Full details of the model fitting process for
this analysis are given in Supplementary Material, avail-
able as Supplementary data at IJE online. Briefly, each
patient’s data were expanded into monthly intervals, and
pooled logistic regression models were fitted to estimate
stabilized IPTW.14,20 Since we assumed patients remained
exposed to metformin after their first prescription until
the end of data collection or censoring, the probability of
initiating metformin was estimated in each monthly inter-
val up to and including the interval of metformin initia-
tion. Patients who initiated metformin at diabetes
diagnosis or who had the outcome in the first interval
were not included in the weighting model, but contrib-
uted to the model for the effect of metformin on cancer
(the ‘outcome model’) with a constant weight of one (see
Supplementary Material, available as Supplementary data
at IJE online; and Figure 1). The model for the denomina-
tor of the weight included time since study entry as the
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underlying time scale, modelled as a restricted cubic
spline with knots at 0, 10, 25 and 120 months. Baseline
covariates included in the model were: time between dia-
betes diagnosis and study entry (restricted cubic spline
with knots at 0, 4 and 120 months); age in years (<45,
45–59, 60–75, >75); sex; calendar year (before 1995,
1995–99, 2000–04 and 2005 onwards); smoking (cur-
rent, ex, never); alcohol consumption (non-drinker, ex-
drinker, current drinker unknown quantity: rare drinker
<2 units (u)/day (d), moderate drinker 3-6 u/d, excessive
drinker >6 u/d); BMI (kg/m2) (<25, 25–29, 30–35 and
>35); HbA1c (<6%, 6–6.5%, 6.5–7%, 7–8%, 8–10%
and >10%); and indicator variables for: use of statins in
the year preceding baseline; use of non-steroidal anti-in-
flammatory drugs (NSAIDs) in the year preceding base-
line; use of anti-hypertensives in the year preceding
baseline; history of cardiovascular disease (CVD); and
history of chronic kidney disease (CKD). Time-varying
covariates included: HbA1c in the previous month; BMI
in the previous month; and indicator variables for: use of
statins in the previous year, use of NSAIDs in the previous
year, use of anti-HTs (anti-hypertensives) in the previous
year; history of CVD; and history of CKD. Last
observation carried forward (LOCF) was used to impute
time-varying covariates going forward from study entry,
if not measured in a particular interval. All baseline risk
factors and time since study entry were entered into the
model for the numerator of the weight.14,20 Stabilized
inverse probability of censoring weights (IPCW) were
calculated using a similar approach to account for non-
informative censoring, and the distribution of the com-
bined treatment and censoring weights was examined.21
Weights were truncated at 0.1 and 10.
The effect of metformin use on risk of cancer was esti-
mated using pooled logistic regression models with time
since study entry included in the model (as a cubic spline
with the same knot points as the weighting model) to ap-
proximate a Cox proportional hazards model allowing for
time-varying weights.22 Exposure to metformin was mod-
elled using a binary variable to represent current treatment.
For composite cancer endpoints, exposure was also mod-
elled by time since first metformin prescription (assumed
equivalent to cumulative time on metformin) categorized
as no medication, 0–6 months, 6–12 months, 1–2 years,
2–5 years, 5–7 years and >7 years), as a time-varying
exposure.
Figure 1. Flow chart to show how final analysis samples were obtained from 98 080 patients in CPRD with incident T2DM, who were cancer free at
time of diabetes diagnosis; a55 629 contribute to model for censoring weights; b54 342 contribute to the outcome models; c54 342 less those initiating
metformin at baseline (6105) and 48 of the 49 524 treatment-naı¨ve at study entry who had a cancer diagnosis in month 1 (not shown on figure) con-
tributing to the model for the inverse probability of treatment weights (n ¼ 48 661).
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Four outcome models were fitted to evaluate the effect
of metformin on cancer risk. The first three models were
unweighted models with varying levels of confounder ad-
justment, namely: model 1—minimal adjustment (adjusted
for baseline age, gender, smoking, alcohol and calendar
year of diabetes onset); model 2—full baseline adjustment
(as model 1 plus all other baseline covariates); model 3—
adjustment for all baseline and time-dependent covariates.
The fourth model (the MSM) was a weighted model us-
ing the joint treatment and censoring weights. All baseline
covariates included in the model for the numerator of the
weights were included as covariates in the MSM. Both
weighting and outcome models were repeated using re-
stricted cubic splines for age, HbA1c and BMI, to investi-
gate the impact of possible model mis-specification from
inappropriate covariate form. All analysis was performed
in Stata v.14.23 All code lists used in this study are avail-
able on the London School of Hygiene and Tropical
Medicine (LSHTM) data compass.
Sensitivity analyses
The three main sensitivity analyses were as follows. First,
we varied how far forward the cancer diagnosis dates were
brought (0 and 12 months), to assess the impact of differ-
ent latency periods. Second, the interval length used was
changed from 1 to 3 months. Third, we explored the effect
of fitting treatment models separately by calendar period.
More detail regarding the methods for these sensitivity
analyses, and details of further (secondary) sensitivity anal-
yses, are given in Supplementary Methods, available as
Supplementary data at IJE online.
Results
Cohort description
A total of 98 080 patients with incident T2DM, aged
30–90 and with no history of any cancer at the time of
diabetes diagnosis, were identified; 55 629 patients were
eligible to enter the study (Table 1). The main reasons for
non-inclusion were lack of HbA1c or BMI data before
treatment initiation (Figure 1). The mean age at diabetes
diagnosis was 62 years [standard deviation (SD) 12 years].
Median follow-up time was 2.9 years [interquartile range
(IQR) 1.3 to 5.4 years], with 40% of included person-time
on metformin.
During follow-up 2530 cancers were observed, with
crude event rates for no medication and for metformin of
11.4 per 10 000 person-years and 9.4 per 10 000 person-
years. respectively. There were 266 prostate, 241 breast,
185 lung, 226 colorectal and 50 pancreatic cancers
observed during follow-up. The full breakdown of incident
cancer types as defined by ICD-10 codes is given in
Supplementary Table 1, available as Supplementary data
at IJE online.
Inverse probability weight estimation
The individuals who were more likely to initiate metformin
had higher HbA1c, higher BMI, were of younger age and
had a later calendar year of diagnosis. Model outputs for
the estimation of both treatment and censoring weights are
presented in Supplementary Tables 2–5, available as
Supplementary data at IJE online. Following truncation,
the mean of the weights was 1.00 (SD 1.09), with 1st and
99th percentiles of 0.1 and 6.48, respectively
(Supplementary Tables 6 and 7, available as
Supplementary data at IJE online).
Table 2 presents estimates of the hazard ratios (HRs)
for the effect of metformin vs no medication on cancer risk
in patients with newly diagnosed T2DM. For all cancer
types examined except colorectal cancer, use of the MSM
increased the HR compared with standard statistical meth-
ods that could not appropriately account for time-
dependent confounders affected by previous treatment. For
all cancers combined, this change was relatively small in
magnitude, and all models were generally consistent with
no effect of metformin on risk of cancer. For specific can-
cers, the changes between the unweighted and weighted
models were more noticeable, though confidence intervals
were wide. For pancreatic cancer, all models estimated an
increased risk with metformin use, with the highest excess
risk estimated by the MSM [HR 3.11, 95% confidence in-
terval (CI) 1.24, 7.76]. For colorectal cancer, the MSM es-
timated a reduction [HR 0.71, 95% CI 0.43, 1.18] in risk
of cancer in patients using metformin vs no medication.
When stratifying by cumulative exposure to metformin,
the MSM gave results consistent with no effect of metfor-
min on risk of all cancers combined for all time periods,
though precision of the estimates reduced as the length of
exposure increased, due to loss of power (Figure 2). The
unweighted models had similar results, though for all can-
cer excluding NMSC these models tended to estimate a
lower risk with metformin use for most time periods, albeit
with confidence intervals that overlapped those from the
weighted analysis (Figure 2; Supplementary Tables 8 and
9, available as Supplementary data at IJE online).
Sensitivity analyses
None of the sensitivity analyses produced meaningfully dif-
ferent results to those observed in the primary analysis (see
Figure 3; and Supplementary Figure 1, available as
International Journal of Epidemiology, 2019, Vol. 0, No. 0 5
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Supplementary data at IJE online). Outcome models using
cubic spline parameterizations of continuous covariates
gave similar results (Supplementary Table 10, available as
Supplementary data at IJE online).
Discussion
We found no evidence of association between metformin
use and overall risk of cancer in patients with T2DM. This
finding was consistent across a range of sensitivity analy-
ses, and in analyses stratified by cumulative exposure to
metformin. We also found no evidence of association
between metformin and breast, colorectal or lung cancer,
though precision was lower for these outcomes. We ob-
served an increased risk of pancreatic cancer.
The majority of well-designed previous studies have
compared new users of metformin with new users of an
alternative first-line diabetes therapy such as a sulphony-
lurea, with covariate adjustment at the time of first expo-
sure.9 Although answering a slightly different question, the
results of these studies are generally consistent with the
analyses presented here even where causal models to ac-
count for time-dependent confounding were not used.5,6,24
One study, using causal methodology to account for
Table 1. Demographics of included patients from the CPRD at study entry
No medication N ¼ 49 524 Metformin N ¼ 6105 Total N ¼ 55 629
Mean (SD) median, 25th percentile-75th percentile)
Age at diagnosis (years) 62.2 (12) 63, 54-71 57.6 (11.8) 57, 49-66 61.7 (12) 62, 53 -71
HbA1c (%) at study entry 7.2 (1.6) 6.8, 6.2-7.7 9.4 (2.3) 9, 7.4-11 7.5 (1.8) 6.9, 6.3-8
BMI (kg/m2) at study entry 31.6 (6.3) 30.7, 27.3-34.9 33.4 (6.9) 32.3, 28.6-37.1 31.8 (6.3) 30.9, 27.5-35.2
N (%)
Gender
Male 27 763 (56.1) 3594 (58.9) 31 357 (56.4)
Female 21 761 (43.9) 2511 (41.1) 24 272 (43.6)
History of chronic kidney disease
No 46 463 (93.8) 5866 (96.1) 52 329 (94.1)
Yes 3061 (6.2) 239 (3.9) 3300 (5.9)
History of cardiovascular disease
No 41 868 (84.5) 5479 (89.7) 47 347 (85.1)
Yes 7656 (15.5) 626 (10.3) 8282 (14.9)
Use of statins in previous year
No 25 035 (50.6) 2739 (44.9) 27 774 (49.9)
Yes 24 489 (49.4) 3366 (55.1) 27 855 (50.1)
Use of NSAID in previous year
No 39 575 (79.9) 4999 (81.9) 44 574 (80.1)
Yes 9949 (20.1) 1106 (18.1) 11 055 (19.9)
Use of antihypertensive in previous year
No 18 048 (36.4) 2767 (45.3) 20 815 (37.4)
Yes 31 476 (63.6) 3338 (54.7) 34 814 (62.6)
Smoking status
Non 20 132 (40.7) 2449 (40.1) 22 581 (40.6)
Current 8746 (17.7) 1287 (21.1) 10 033 (18.0)
Ex 20 646 (41.7) 2369 (38.8) 23 015 (41.4)
Alcohol consumption
Non-drinker 5770 (11.7) 884 (14.5) 6654 (12)
Ex-drinker 3474 (7) 529 (8.7) 4003 (7.2)
Current drinker quantity unknown 979 (2) 121 (2.0) 1100 (2.0)
Rare drinker <2 u/d 11 543 (23.3) 1484 (24.3) 13 027 (23.4)
Moderate drinker 3-6 u/d 22 934 (46.3) 2570 (42.1) 25 504 (45.8)
Excessive drinker >6 u/d 4824 (9.7) 517 (8.5) 5341 (9.6)
Calendar year of onset
1990-95 134 (0.3) 0 (0) 134 (0.2)
1995-2000 1708 (3.5) 20 (0.3) 1728 (3.1)
2000-05 12 764 (25.8) 595 (9.8) 13 359 (24)
After 2005 34 918 (70.5) 5490 (89.9) 40 408 (72.6)
NSAID, non-steroidal anti-inflammatory drug.
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informative loss to follow-up, compared cancer risk between
new users of metformin and new users of sulphonylureas.6
Though a different comparison group was used, results were
consistent with our findings: the authors found no difference
in risk of any cancer [HR for metformin vs sulfonylureas
0.94, 95% CI 0.85, 1.04]. Findings for individual cancers
were broadly consistent with our individual cancer esti-
mates, except for a suggestion of a protective effect of met-
formin on pancreatic cancer, in contrast with the increased
risk of pancreatic cancer with metformin use vs no medica-
tion in the present study. An early symptom of
pancreatic cancer may be onset of type 2 diabetes, and it is
possible that the increased risk we observed was driven by
undiagnosed cancer causing more severe onset and/or an in-
dication for metformin that is not captured by our weighting
models. Although we attempted to remove such reverse cau-
sality using a 6-month lag time, this may have been insuffi-
cient for pancreatic cancer, which is often diagnosed late.
Figure 2. Hazard ratios and 95% confidence intervals for effect of metformin use on risk of cancer, estimated by time since first metformin prescrip-
tion. Top: All cancers including NMSC. Bottom: All cancers excluding NMSC. Estimates from three standard analysis methods (1–3) and MSM with
joint IPTW and IPCW (4). Model 1: Minimal adjustment for confounding: adjustment for age, gender, smoking status and alcohol status and year of
onset of diabetes. Model 2: Full adjustment for baseline covariates: model 1þbaseline adjustment for: HbA1c, BMI, use of other medications in previ-
ous year (NSAIDS, statins, antihypertensive drugs), history of chronic kidney disease (CKD) and cardiovascular disease (CVD). Model 3: Full adjust-
ment for baseline covariates with time-dependent covariates added: model 2þ adjustment for time-updated HbA1c, BMI, and history of CVD, CKD
and use of other medications in the past 12months. Model 4: As model 2, weighted using joint IPTW and IPCW (MSM with IPTW and IPCW). HRs ap-
proximated from a pooled logistic regression. NMSC, non melanoma skin cancer.
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For most outcomes the MSMs produced results that were
similar to those obtained via standard analysis methods with
baseline adjustment only, despite the hypothesized presence of
time-dependent confounders affected by previous treatment.
This may suggest that the time-dependent confounding was
not as strong as initially thought, and as such, that previous
well-designed studies would be unlikely to find contrasting
results with a marginal structural model approach. Hicks
(2017)25 found a similar lack of difference in estimates be-
tween standard analysis methods and MSMs, when compar-
ing metformin with any other oral glucose-lowering drug for
risk of virally associated cancers. In that study, 86% of indi-
viduals prescribed metformin during follow-up were using it
at the time of cohort entry, meaning that only a small propor-
tion of individuals would have been affected by time-depen-
dent confounding. In our analysis, there were many more
patients unexposed to metformin at study entry, but the over-
all median time to initiation was only 2 months (IQR 1–
16months). Therefore it is possible that not enough patients
were initiating treatment far enough after baseline for the
time-varying confounders to change sufficiently. In the analysis
of cumulative medication, the differences in estimates for
more than 7 years’ exposure between standard methods and
MSM were greater, which is consistent with this explanation.
It is also possible that in combining all cancers, any po-
tential time-dependent confounding was masked because
the confounding acts in opposite directions for different
cancers. In particular, the association between BMI and
risk of cancer has been shown to differ by cancer type.10,26
The slightly larger observed changes between standard
models and MSMs in some of the site-specific analyses sup-
port this possibility, though the site-specific analyses did
not produce results that suggested that a protective effect
of metformin was being masked by combining cancers into
a composite endpoint.
An important limitation of this analysis is that the aver-
age follow-up time of patients in this study was relatively
short. With a median time of 2.9 years, we acknowledge
that there may have been insufficient follow-up in enough
patients to detect any causal effect of metformin on cancer.
The decision to censor at initiation of any other therapy in
our analyses contributed to this reduced follow-up time,
but with use of IPCW to adjust for informative censoring,
this approach was deemed the most appropriate way to re-
move issues of treatment switching. It should also be noted
that previous studies of metformin and cancer with con-
trasting results also had average follow-up times that are
broadly comparable to our study.3,4 By stratifying by
Figure 3. Hazard ratios and 95% confidence intervals for effect of metformin use on risk of cancer for primary analysis (left) and 4 sensitivity analyses.
Estimates from three standard analysis methods (1–3) and MSMwith joint IPTW and IPCW (4). Model 1 – Minimal adjustment for confounding: adjust-
ment for age, gender, smoking status and alcohol status and year of onset of diabetes. Model 2 Full adjustment for baseline covariates: Model 1 þ
baseline adjustment for: HbA1c, BMI, use of other medications in previous year (NSAIDS, statins, antihypertensive drugs), history of chronic kidney
disease (CKD) and cardiovascular disease (CVD). Model 3 – Full adjustment for baseline covariates with time-dependent covariates added: Models 2
þ adjustment for time updated HbA1c, BMI, and history of CVD, CKD and use of other medications in the past 12 months. Model 4 – As Model 2,
weighted using joint IPTW and IPCW (MSM with IPTW and IPCW). HRs approximated from a pooled logistic regression.
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length of exposure to metformin in a secondary analysis, it
was possible to obtain an estimate for the effect of 5–7 and
more than 7 years of metformin use on cancer risk, and the
point estimates remained close to the null. However, we
must acknowledge that due to fewer numbers with long-
term follow-up, confidence intervals for more than 7 years
of exposure cannot rule out up to a 51% decreased risk or
103% increased risk for all cancers combined.
Additionally, there may have been residual confounding by
physical activity and diet, data for which are not available
in the CPRD, or by smoking, for which only crude data
were available.
Previous studies have found that cancer diagnoses taken
from CPRD primary care data have good concordance
with external sources, and have a low false-positive
rate.27,28 However, feedback of cancer diagnoses from sec-
ondary care to GPs may be imperfect, and we cannot
exclude the possibility of some under-ascertainment of our
outcomes by relying on primary care data alone. The effect
of any under-ascertainment of outcomes on the estimated
effects of metformin is likely to be small, since the hazard
ratio remains unbiased when the misclassification affects
sensitivity but not specificity.29
In our analysis, only a single prescription was required
to be considered exposed to metformin, and it was
assumed that the patient remained exposed until there was
evidence of a change in medication; however, this
approach would not take into account non-adherence to
prescribed medication or cessation of all antidiabetic ther-
apy. It should also be acknowledged that patients appar-
ently off treatment may have been receiving medication
from specialist diabetes clinics or other sources. However,
since diabetes is predominantly managed in primary
care,30 this is unlikely to affect the results substantially.
Indeed, a strength is that the patients captured by our
study, namely a cohort of newly diagnosed type 2 diabetes
patients receiving primary care from their general practi-
tioner, is a highly relevant population for this question—
especially since metformin and lifestyle changes are both
common first-line interventions in clinical practice.2
Even after weight stabilization, there were extremely
large weights for some individuals, usually driven by the
characteristic of having a high HbA1c but not initiating
metformin. Truncation of the stabilized weights was there-
fore necessary, which may have resulted in re-introducing
time-dependent confounding. However, we only truncated
the top 0.6% of the weights, meaning that under the as-
sumption that the weighting model was correctly specified,
the amount of confounding re-introduced is likely to be
small.
We found that many patients had missing HbA1c or
BMI at the time of diabetes diagnosis. Use of multiple
imputation was not considered since there is limited re-
search on the use of multiple imputation with MSMs, and
it is likely impractical to combine these methods in a large
dataset, due to computational intensity. To increase num-
bers, patients entered the study at the first point (at or after
diabetes diagnosis) at which they had data on all covari-
ates, as long as this was before any treatment was initiated.
Using this approach instead of a complete case analysis in-
creased the sample size by about 20 000 patients, and since
75% of these patients entered the study within 6 months of
their diagnosis date, it was considered that this would not
cause serious bias. However, this approach resulted in the
exclusion of a large number of individuals who initiated
treatment before they obtained measurements for HbA1c
and BMI. This could induce selection bias if the reason for
not having measurements was related to cancer risk,
though there is no clear reason why this would be true.
We believe this to be the first published study to assess
cancer risk associated with metformin use vs no medication
while appropriately adjusting for time-dependent confound-
ers affected by previous treatment. We found no evidence
that metformin has a protective effect on cancer risk in
patients with type 2 diabetes—a result consistent with some
existing studies using new-user active comparator designs
and an intention to treat approach. Although we acknowl-
edge loss of precision, our results had consistent estimates
close to the null when looking by length of exposure. As
such, these results add weight to the view that the large pro-
tective effects previously observed were not causal.
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